What conclusions can we draw from these preliminary data for the use of BTK inhibitors to treat the hyperinflammatory immune response in patients with severe COVID-19?
How are you using telemedicine or other strategies to manage your patients with CLL during the COVID-19 pandemic?
How are you managing your patients with CLL during the COVID-19 pandemic? Here, I share my experiences during the height of the pandemic in New York City and offer recommendations to minimize the risk to your patients.
As a physician and CLL survivor, I share insights on the patient’s experience in the ongoing COVID-19 pandemic plus recommendations for counseling patients with CLL on how best to protect their physical and mental health.
Our understanding of how COVID-19 affects our patients with CLL continues to evolve. Here, I share my perspective on treatment modifications during the pandemic, using IVIg as COVID-19 prophylaxis, the role of BTK inhibition, and counseling patients on COVID-19 risk.
With the first 6 months of the COVID-19 pandemic behind us, I share how my management of patients with CLL has evolved based on experience and key data emerging on COVID-19 risk in patients with CLL.
Here I discuss 2 interesting cases from my practice: an older patient who needed to initiate therapy but was afraid to come to the clinic and a patient who developed COVID-19 while receiving venetoclax.
What are the latest data on BTK inhibitors to treat COVID-19? How are you managing your patients with CLL going forward? Here, I share my experiences and thoughts on the implications of the latest data and emerging vaccine approvals for patients with CLL.